ALPCO Calprotectin ELISA - Measurement of Calprotectin Levels in Human Stool

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

424 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-05-01

Study Completion Date

2019-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ALPCO Calprotectin ELISA is an in vitro diagnostic test intended to quantitatively measure concentrations of fecal calprotectin in human stool samples. Calprotectin is a protein biomarker of mucosal inflammation. Measurement of calprotectin can aid in the diagnosis of Inflammatory Bowel Diseases (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC), as well as aid in the differentiation of IBD from Irritable Bowel Syndrome (IBS) when used in conjunction with other diagnostic testing and the total clinical picture. This study will estimate the predictive values of a negative (NPV) and positive (PPV) test by utilizing the assay outcomes of the ALPCO Calprotectin ELISA.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

NCT06810518

Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) Inflammatory Bowel Syndrome

RECRUITING

ALPCO/Calprotectin CLIA Assay: Expected Values of Calprotectin in Healthy Subjects

NCT07089420

IBD (Inflammatory Bowel Disease) IBS - Irritable Bowel Syndrome Crohn Disease (CD) +1 more

RECRUITING

Pro-active Fecal Calprotectin Monitoring PROMOTE-UC

NCT03549988

Ulcerative Colitis

ACTIVE_NOT_RECRUITING

Head-to-head Comparison of Two Fecal Biomarkers to Screen Children for IBD

NCT02197780

Abdominal Pain Rectal Bloodloss Diarrhea +4 more

COMPLETED

Value of Fecal Calprotectin

NCT00577928

Calprotectin Inflammatory Bowel Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Bowel Diseases Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

* \>18 years of age
* Patient must present with signs and symptoms of IBS or IBD
* Patient must be scheduled for a colonoscopy
* All results of the colonoscopy including histology must be provided to study site and sponsor.
* Medical Chart review may be required to confirm diagnosis of IBS or IBD
* Patient must not have taken NSAIDs for at least 2 weeks prior to participating in the study. Patients may be advised of the study and if report taking NSAIDS may be enrolled in the study after the patient has stopped use of NSAIDS for a minimum of 2 weeks.
* For normal patient population - study participants must present with no signs or symptoms of IBS or IBD, must not have taken NSAIDs for at least a period of 2 weeks and must be willing to provide a stool sample.
* Sample must be collected at least 2-3 days prior to colonoscopy

* Male or female, ≥18 years of age.
* No abdominal complaints and no history of IBS, IBD, or other chronic intestinal disorder, confirmed by medical history and physical examination at enrollment.
* May have undergone colonoscopy with negative findings within the past 1 month or may have no recent colonoscopy, but scheduled for routine screening colonoscopy.
* Able to understand the study and the task required, and sign the ICF.

Exclusion Criteria

* patient under the age of 18
* Patient taking NSAIDs
* Patients not presenting with signs or symptoms of IBS or IBD with the exception of 100 normal patients to be included in the study. Fifty (50) presenting for routine colonoscopy and 50 patients presenting with no disease symptoms and not scheduled for a colonoscopy.
* Patients not scheduled to have an colonoscopy unless enrolled in the study as normal population

* Unable or unwilling to provide a stool specimen.
* Have taken protein pump inhibitors (PPIs) or H2-receptor antagonists for control of upper GI disease within the previous 2 weeks.
* Have taken NSAIDs (including aspirin) on within 2 weeks of study enrollment.

Minimum Eligible Age

22 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes